Kornimate/medical-research-clean huggingface dataset:
implantation of iodine125-seeds combined with chemotherapy in the treatment of metastatic pancreatic carcinoma

Conditions: Metastatic Pancreatic Cancer

Summary: the goal of this clinical trial is to evaluate the clinical efficacy and safety of endoscopic ultrasonography (eus)-guided radioactive iodine 125 seeds in combination with ag regimen chemotherapy for the treatment of metastatic pancreatic cancer. the main questions it aims to answer are: * whether the combination of minimally invasive endoscopy-guided local radiation therapy with chemotherapy may improve overall survival * the adverse events of the combination therapy participants will receive the implantation of radioactive seeds under eus guide. 48h after implantation, chemotherapy with gem/nab-p given on days 1 and 8 of each 21-day cycle will be conducted. researchers will compare the i125+ag group with the group that takes ag chemotherapy alone to see if the overall survival can be improved.


Eligibility criteria:
inclusion criteria: (before the trial, subjects must meet all of the requirements listed below in order to be enrolled) 1. 18 to 80 years old; 2. stage iv pancreatic ductal adenocarcinoma with distant metastases confirmed by clinical, imaging, and pathology, and the primary and metastatic mass can be measured on imaging. 3. no treatment history of chemotherapy, radiotherapy, or surgery 4. expected survival \> 6 months 5. ecgo score of 0-2 6. eligible for chemotherapy (white blood cell \> 3.5×109/l, neutrophil value \> 1.5×109/l, hemoglobin \> 80g/l, platelets \> 100×109/l, albumin \> 25g/l, alanine aminotransferase or aspartate aminotransferase ≤ 3 times the upper limit of normal and total bilirubin level ≤ 34.2umol/l, creatinine \< 176.8 umol/l, normal ecg) 7. signed written informed consent; exclusion criteria: 1. contraindication of eus-guide procedure or technical infeasibility (e.g.,coagulation disorder, anatomical changes, large vessels along the puncture path) 2. pregnant or breastfeeding 3. presence of brain metastases 4. presence of deep vein thrombosis or pulmonary embolism 5. presence of hiv, hbv, hcv infection or other uncontrollable active infection 6. hypersensitivity to chemotherapy drugs 7. history of other malignancies within 5 years 8. peripheral neuropathy or interstitial lung disease within 5 years 9. patient is enrolled in any other clinical protocol or investigational trial.

Keywords: iodine 125 eus-guided implantation chemotherapy
evaluation of sub-syndromal symptoms after acute depressive episode in bipolar disorder

Conditions: Bipolar Disorder; Sub-syndromal Symptoms

Summary: the study aims to evaluate: * the frequency of subsyndromal symptoms or disorders observed during interepisode phases in bipolar patients, particularly after a depressive episode in which these subsyndromal disorders are the most frequent * the functional impact of these disorders, factors or symptom thresholds associated with functional remission, and factors associated with symptomatic remission over a sufficient follow-up (12 months).

evaluation of sub-syndromal symptoms after acute depressive episode in bipolar disorder

Eligibility criteria:
inclusion criteria: * adult patient with a diagnosis of bipolar disorder according to dsm-iv criteria currently followed up by the investigator in hospital or open-care practice and informed of his/her disease. * for whom the previous episode was a bipolar depression assessed clinically stabilized for at least 4 weeks by the investigator. * able to complete the self-assessment diary weekly exclusion criteria: * pregnant women. * patient included in a clinical trial on an investigational drug or having received an investigational drug in the preceding 30 days. * person deprived of freedom or subject to a guardianship (or ward) order or unable to undergo medical monitoring for geographical, social or psychological reasons.

Keywords: bipolar disorders sub-syndromal symptoms acute depressive episode symptomatic remission functioning remission
evaluation of cross mental nerve transfer in restoration of chin &lip sensation post inferior alveolar nerve injury

Conditions: Injury of Mental Nerve of One Side

Summary: evaluation of cross mental nerve transfer in restoration of chin \&lip sensation post inferior alveolar nerve injury


Eligibility criteria:
inclusion criteria: * patients with hemimandiblectomy * patients with injured inferior alveolar nerve which not showing any healing after 9 months * age group : from 15 to 60 years old * no sex predilection * patients with no contraindications to surgical intervention exclusion criteria: * • patients with systemic condition counteracting with the surgical procedure.
quality of life in barrett's esophagus and gastro-esophageal reflux disease

Conditions: Barrett's Esophagus; Gastroesophageal Reflux Disease

Summary: to compare the overall quality of life of patients with no barrett's esophagus , non-dysplastic barrett's esophagus (ndbe), barrett's esophagus with low grade dysplasia (lgd), and barrett's esophagus with high grade dysplasia (hgd). we also compare the overall quality of life of barrett's esophagus patients with severe gastroesophageal reflux disease (gerd) symptoms to those with no gerd symptoms

the presence of gerd symptoms is associated with a significant decrease in quality of life.while a diagnosis of barrett's esophagus is also associated with a decrease in quality of life, these studies evaluated barrett's esophagus patients with gerd symptoms.it is unclear whether decrements in quality of life from cancer risk in patients with barrett's esophagus are due to actual cancer risk or a patient's false perception.here we compare the overall quality of life of patients with no barrett's esophagus , non-dysplastic barrett's esophagus (ndbe), barrett's esophagus with low grade dysplasia (lgd), and barrett's esophagus with high grade dysplasia (hgd). the investigators will also compare the overall quality of life of barrett's esophagus patients with severe gastroesophageal reflux disease (gerd) symptoms to those with no gerd symptoms. finally the investigators will compare the overall quality of life of patients with a perceived low risk of esophageal cancer to those with a perceived high risk of esophageal cancer

Eligibility criteria:
inclusion criteria: age 18 or above at least one of the following: previous diagnosis of barrett's esophagus presence of gerd symptoms per patient report exclusion criteria: none

Keywords: barrett's esophagus gastroesophageal reflux disease quality of life
acceptability of hepatitis b vaccination in general practitioners and paediatricians

Conditions: Hepatitis B

Summary: the present study is conducted in order to assess the acceptability of hepatitis b vaccination in french general practitioners and peadiatricians before and after reimbursement of the paediatric vaccine infanrixhexa. two data measurement time points are planned, first before reimbursement and after reimbursement.

the aim of the study is to assess the acceptability of hepatitis b immunization among general practitioners and open-care paediatricians. this is a national, repeated transversal epidemiological study with two data measurement time-points over a period of two years (t1 in 2009, t2 in 2011, two different samples of physicians) in order to assess immunization practices before introduction of the reimbursement of infanrixhexa®, during the transition period and then during the period following reimbursement of the vaccine. at each collection time-point, two patient age groups will be investigated: 12-15 months and 24-27 months, thus providing measurements before/after reimbursement.

Eligibility criteria:
inclusion criteria: • children on the eligibility register complying with the investigator's immunization policy (children followed by the investigator since their birth, whose immunization regimen has been managed by the investigator). exclusion criteria: * children on the eligibility register not complying with the investigator's immunization policy. * refusal of the patient.

Keywords: vaccination acceptability hepatitis b
safety and efficacy of mix vaccine in lung carcinoma patient

Conditions: Lung Neoplasms

Summary: the purpose of this study is to evaluate the safeness and effectiveness of mix vaccine (mv). enrolled patients will receive standard treatment according to national comprehensive cancer network (nccn) guide line with or without combining mv injection. the efficacy and side effect will be compared between the two groups.

in the study, after evaluation of the general and physical status, eligible patients will be enrolled and randomly assigned into two arms at an 1:1 ratio. in the control arm patients will be receiving standard therapy according to national comprehensive cancer network (nccn) guide line (control group) and in experimental arm, patients will be receiving simultaneous standard therapy and injection of mix vaccine (mv). mv will be injected weekly till disease progression. blood sample will be obtained at baseline and every week before mv injection for the assessment of clinical hematology, biochemistry measurements and immunology index (including immunoglobin, interleukin and interferon). patients will be evaluated for toxicity throughout the study. side effect, progression free survival, immunology index and general status will be recorded.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with lung carcinoma based on histology 2. evaluable lesions on imaging study 3. without known immunodeficiency 4. age \>18 and \<80 years ago exclusion criteria: 1. patients is unable or unwilling to sign informed consent 2. any autoimmune disorder, which is currently being treated with prednisone or any other immune suppressive medication 3. positive hiv and/or rpr (rapid plasma reagin ) 4. female patient who is pregnant or breast feeding 5. patients, based on the opinion pf the investigator, should not be enrolled into this study 6. prior anti-cancer vaccine or biological immunotherapy 7. allergic to any known ingredient of the mv compound

Keywords: mix vaccine, lung neoplasms, immunotherapy
get out of your head 2.0: evaluation of an online prevention campaign and updated website for men

Conditions: Suicide; Suicidal Ideation

Summary: the primary objective of this study is to evaluate the perceptions and evaluations of men with suicidal thoughts, regarding the new "get out of your head" campaign and the updated website. the findings will inform potential adjustments to enhance the campaign and website as needed.

in a previous study (bun: b6702024000090) the authors focused on identifying these barriers and needs among adult men experiencing suicidal thoughts and their healthcare providers. findings from this needs assessment suggest that men with suicidal ideation often perceive a lower need for help and hold attitudes that inhibit help-seeking and sustained engagement in care. these attitudes appear closely linked to societal gender norms around emotional openness, self-reliance, and the perceived responsibility to provide for a family. furthermore, men experiencing suicidal thoughts expressed a desire for information on certain topics that may currently be unavailable. to address these gaps, a new awareness campaign is being developed, alongside updates to the existing "get out of your head" website (original: www.komuitjekop.be), incorporating necessary information. the campaign and website updates are being shaped through a participatory co-creation process involving men with a history of suicidal thoughts to ensure relevance and leverage their experiential knowledge (bun: b6702024000420). in this approach, men with lived experience are central to the decisions on the design and content of the tools. additionally, input from experts in healthcare and masculinity, as well as international research, is being integrated. once the campaign is developed and the website (www.komuitjekop.be) is updated, the authors aim to evaluate how these resources are perceived by men with suicidal thoughts to further refine these suicide prevention efforts. the primary objective of the current study is to evaluate the perceptions and evaluations of men with suicidal thoughts, regarding the new "get out of your head" campaign and the updated website. the findings will inform potential adjustments to enhance the campaign and website as needed.

Eligibility criteria:
inclusion criteria: * men (≥ 18y/o) * experienced suicidal thoughts in the past three year * access to a smartphone, tablet, or computer with internet connection * proficiency in dutch exclusion criteria: * does not meet the specified inclusion criteria.
motor learning for upper limb hemiparesis after stroke

Conditions: Stroke; Hemiparesis

Summary: the purpose of this research is to learn about practice conditions that may benefit stroke survivors when learning to use their more affected arm to perform a task. participants will be randomized into two groups. experimental and control groups will differ by one practice variable that will not be disclosed until completion of testing procedures. participants will practice a motor task using both their more and less affected arms for two consecutive days. a pre-test will be administered on day 1 before the training begins. immediate transfer of learning will be administered on day 2 after the completion of training. delayed (24-hour) retention and transfer tests will be administered on day 3.

stroke involves loss of blood flow to the brain and can cause impaired upper limb motor function, resulting in long term disability. targeted motor learning interventions can improve skill acquisition and functional upper limb use after stroke. for example, repetitive practice of a motor task has been shown to improve motor learning outcomes. however, more research is currently needed to identify important active ingredients in complex motor learning interventions and determine the most effective approaches for improving upper limb recovery after stroke. the purpose of this study is to investigate the impact of a specific practice variable on motor learning for individuals with upper limb hemiparesis after stroke. this research will inform the development of future stroke rehabilitation interventions aimed at improving skill acquisition and motor learning.

Eligibility criteria:
inclusion criteria: * at least 6 months following stroke (ischemic or hemorrhagic) * upper limb weakness resulting from the stroke * able to follow 2-step commands * box and block test score of 3-60 * intact proprioception at the index finger of the weaker arm * english speaking exclusion criteria: * severe neglect (score of 2 on extinction and inattention items of nihss) * arm pain that limits movement or loss of functional range of movement (contracture) * unable to give informed consent * received botox within the past 3-months

Keywords: stroke hemiparesis rehabilitation motor learning
bromelain and escin in the reduction of postoperative sequelae in periodontal and implant surgery

Conditions: Postoperative Pain; Edema; Swelling Lips & Face

Summary: a randomized clinical trial will be performed in parallel, placebo controlled, triple-blind to evaluate the effectiveness of the association bromelina and horse-chestnut (titrated in escin) (noflogo®, mavenpharma s.r.l., rome, italy) in the management of post trauma-surgery following surgery periodontal and implant surgery.

at least 50 volunteers between the ages of 18 and 50, will be enlisted, with the need to perform one of the interventions described above and that fall within the criteria of inclusion. the study will be carried out in accordance with the helsinki declaration on in vivo studies and will be initiated with the approval of the internal review board of the university of l'aquila. the protocol follows the guidelines of the consort statement for parallel studies and will be recorded on the data base clinicaltrials.gov.

Eligibility criteria:
inclusion criteria: * no signs of gingival inflammation; * fmbs and fmps ≤ 20% after non-surgical causal therapy (only for patients undergoing periodontal surgery) * smokers have to indicate how many cigarettes they smoke and how long have they been smoking exclusion criteria: * gingival inflammation * positive anamensis for relevant systemic pathologies (renal, cardiovascular, hepatic, infectious, neoplastic and diabetological) * treatment with anti-inflammatory and/or antibiotics in the two weeks preceding the start of the trial * history of allergy to one or more components of the medication to be tested * pregnant women
topical sb-275833 ointment, 1% for the treatment of impetigo

Conditions: Skin Infections, Bacterial

Summary: the goal of this study is to determine if topical sb-275833 ointment, 1% is as safe and effective as topical sodium fusidate ointment, 2% for the treatment of impetigo in adults and children as young as 9 months of age.

a randomised, observer-blind, multicentre, non-inferiority, comparative, phase iii study of the safety and efficacy of topical 1% sb-275833 ointment, applied twice daily for 5 days, versus topical 2% sodium fusidate ointment applied three times daily for 7 days in the treatment of adult and paediatric subjects with impetigo.

Eligibility criteria:
inclusion criteria: * must have primary impetigo with total lesion area being 100 square centimeters or less. * women who could bear children must have a negative urine pregnancy test and agree to either abstain from sexual intercourse or the use of specific effective contraceptive measures. exclusion criteria: * any signs and symptoms of systemic infection. * any serious underlying disease that could be imminently life threatening.

Keywords: topical antibacterial topical antibiotic impetigo
maribavir for treatment of resistant or refractory cmv infections in transplant recipients

Conditions: Cytomegalovirus (CMV)

Summary: this study will assess safety, antiviral activity, and pharmacokinetics of different doses of maribavir administered orally for up to 24 weeks for treatment of cmv infections that are resistant or refractory to treatment with ganciclovir/valganciclovir or foscarnet in recipients of stem cell or solid organ transplants.


Eligibility criteria:
inclusion criteria 1. be ≥12 years of age. 2. weigh ≥ 40 kg. 3. be a recipient of stem cell or solid organ transplantation. 4. have documented cmv infection in blood or plasma, with a screening value of ≥1,000 dna copies/ml. 5. have a current cmv infection that is resistant (known cmv genetic mutations) or refractory (clinical failure to respond) to treatment with ganciclovir/valganciclovir and/or foscarnet. 6. if female, be either postmenopausal, surgically sterile, or have a negative pregnancy test prior to randomization. 7. be able to swallow tablets. 8. if adult, provide written informed consent. if child (age \<18 years), have a parent/legal guardian who is willing and able to provide written informed consent (with assent from the child when appropriate). 9. be assessed by the investigator to determine whether prophylaxis for non-cmv herpesvirus infections (e.g., herpes simplex virus \[hsv type 1 and type 2\] and varicella zoster virus \[vzv\]) is appropriate according to institutional guidelines or standard practices, keeping in mind that maribavir is not active in vitro against these viruses. exclusion criteria 1. be receiving any other anti-cmv agent(s). 2. have a current cmv infection that is considered resistant or refractory due to inadequate adherence to prior oral anti-cmv treatment. 3. have severe vomiting, diarrhea, or other severe gastrointestinal illness within 24 hours prior to the time of enrollment. 4. have severe hepatic impairment. 5. require mechanical ventilation or vasopressors for hemodynamic support at the time of enrollment. 6. have expected survival less than 6 weeks. 7. be pregnant or breastfeeding. 8. other clinically significant medical or surgical condition.

Keywords: transplant treatment resistant cmv refractory cytomegalovirus
canadian trial of dietary carbohydrates in diabetes

Conditions: Type 2 Diabetes

Summary: a long-term low carbohydrate, high monounsaturated fat diet, compared to a high carbohydrate, low glycemic index diet, results in more rapid progression of diabetes; i.e. increased fasting glucose and glycated hemoglobin, reduced beta-cell function and insulin sensitivity and increased free fatty acids. the deleterious effects of a high carbohydrate diet on plasma lipids are only temporary and do not persist beyond 6 months. a long-term high carbohydrate, low glycemic index diet, compared to a high carbohydrate, high glycemic index diet, improves glycemic control and beta-cell function


Eligibility criteria:
inclusion criteria: * male or non-pregnant/non-lactating females with type 2 diabetes treated by diet alone * age 53-75y * body mass index 25-40kg/m\^2 (caucasian) or 23-40kg/m\^2 (other) * hba1c \<=130% of upper limit of normal of local hospital lab exclusion criteria: * use of any hypoglycemic or anti-hyperglycemic drug within 6 months of randomization * major cardiovascular event or major surgery within 6 months of randomization * serum triglycerides \>10mmol/l * presence of other major debilitating disorder such as liver disease, renal failure or cancer * presence of gastrointestinal disorder or use of drug which is likely to alter gastrointestinal motility or nutrient absorption * use of oral steroids * substance or alcohol abuse * simultaneous participation in another clinical trial * allergy or intolerance to more than one of wheat, barley, corn, oats, potato, legumes, nuts, psyllium, olives, avocado or canola * unwilling or unable to follow the protocol and/or give informed consent * subjects planning to be on holiday for more than 8 weeks in a row or a total of 12 weeks in the year in locations to which they will not take study food